daunorubicin has been researched along with Minimal Disease, Residual in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (10.00) | 18.2507 |
| 2000's | 17 (24.29) | 29.6817 |
| 2010's | 36 (51.43) | 24.3611 |
| 2020's | 10 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Alakel, N; Bornhäuser, M; Chemnitz, J; Döhner, H; Döhner, K; Fransecky, L; Gaidzik, V; Germing, U; Götze, KS; Haas, R; Hänel, M; Hanoun, M; Henning, L; Heuser, M; Holderried, TAW; Holtick, U; Jehn, CF; Kaiser, U; Kobbe, G; Koch, K; Kraus, S; Krause, SW; Kriege, O; Krüger, W; Lauseker, M; Middeke, JM; Morgner, A; Neuerburg, C; Platzbecker, U; Rautenberg, C; Röhnert, MA; Röllig, C; Sauer, T; Schäfer-Eckart, K; Schetelig, J; Schliemann, C; Scholl, S; Schröder, J; Schroeder, T; Severmann, J; Sockel, K; Stelljes, M; Stölzel, F; Thol, F; Unglaub, JM; Verbeek, M; Vucinic, V; Wagner-Drouet, E; Wass, M | 1 |
| Alex, AA; Balasubramanian, P; Balasundaram, N; David, S; Ganesan, S; George, B; Korula, A; Lakshmanan, V; Mathews, V; Palakodeti, D; Palani, HK; Venkatraman, A; Vyas, N | 1 |
| Campana, D; Cheng, C; Coustan-Smith, E; Lins, MM; Lucena-Silva, N; Pedrosa, A; Pedrosa, F; Pedrosa, M; Ramos, AML; Ribeiro, RC; Rivera, GK; Vinhas, E; Zhou, Y | 1 |
| Biffi, A; Buffardi, S; Buldini, B; Carraro, E; Cavallaro, E; Cellini, M; D'Amore, ESG; Damanti, CC; Gallingani, I; Lovisa, F; Micalizzi, C; Mussolin, L; Piglione, M; Pillon, M; Sala, A; Santoro, N; Vinti, L | 1 |
| Bai, L; Chen, H; Chen, HR; Chen, YH; Cheng, YF; Han, W; Huang, XJ; Jia, YP; Liu, KY; Lu, AD; Sun, YQ; Suo, P; Tang, XF; Wang, JB; Wang, Y; Wu, J; Xu, LP; Yan, CH; Zhang, LP; Zuo, YX | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Baker, R; Burt, R; Farah, N; Ibrahim, AR; Kottaridis, PD | 1 |
| Adamkiewicz-Drożyńska, E; Balwierz, W; Ćwiklińska, M; Derwich, K; Karolczyk, G; Kazanowska, B; Kowalczyk, J; Kołtan, A; Krawczuk-Rybak, M; Lejman, M; Machnik, K; Matysiak, M; Mizia-Malarz, A; Młynarski, W; Niedźwiecki, M; Ociepa, T; Owoc-Lempach, J; Płonowski, M; Romiszewski, M; Sobol-Milejska, G; Szczepański, T; Tomaszewska, R; Trelińska, J; Urasiński, T; Urbańska-Rakus, J; Wachowiak, J; Wysocki, M; Zawitkowska, J | 1 |
| Chen, HQ; Fang, JP; Li, CG; Li, CK; Li, JQ; Li, XY; Lin, YD; Liu, RY; Luo, XQ; Sun, X; Sun, XF; Wu, XD; Xu, HG | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Balsat, M; Barraco, F; Baudouin, A; Cadassou, O; Ducastelle, S; Elhamri, M; Fossard, G; Gutrin, J; Hayette, S; Heiblig, M; Labussière, H; Larcher, MV; Plesa, A; Roumier, C; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Avgeris, M; Baka, M; Drakaki, I; Gourgiotis, D; Kossiva, L; Marmarinos, A; Piatopoulou, D; Pourtsidis, A; Scorilas, A; Xagorari, M | 1 |
| Burnett, AK; Cahalin, P; Cavenagh, JD; Couzens, S; Dillon, R; Freeman, SD; Gilkes, A; Grimwade, D; Hills, RK; Jones, G; Khan, N; Khwaja, A; Nielsen, OJ; Russell, NH; Thomas, I; Upton, L; Virgo, P | 1 |
| Coltoff, A; Houldsworth, J; Keyzner, A; Mascarenhas, J; Renteria, AS | 1 |
| Fuhrmann, S; Karawajew, L; Kulozik, AE; Kunz, JB; Ludwig, WD; Möricke, A; Ratei, R; Schabath, R; Schrappe, M; Zimmermann, M | 1 |
| Ali, OM; Baer, MR; Duong, VH; El Chaer, F; Emadi, A; Griffiths, EA; Koka, R; Law, JY; Lee, ST; Sausville, EA; Singh, ZN; Wong, J; Yared, JA | 1 |
| Borowitz, MJ; Campana, D; Carroll, WL; Cheng, C; Choi, JK; Devidas, M; Fulton, RS; Gastier-Foster, J; Hunger, SP; Jay, D; Jeha, S; Karol, SE; Kornegay, N; Larsen, EC; Loh, ML; Mardis, ER; Pui, CH; Raetz, EA; Relling, MV; Robinson, KM; Winick, N; Wood, B; Yang, W | 1 |
| Cai, X; Chen, X; Li, C; Liang, Y; Wang, H; Xia, Z | 1 |
| Bartram, CR; Koehler, R | 1 |
| Eckert, C; Henze, G; v Stackelberg, A | 1 |
| Karawajew, L; Ludwig, WD; Möricke, A; Ratei, R; Schabath, R; Schrappe, M; Zimmermann, M | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Bowman, WP; Campana, D; Coustan-Smith, E; Dahl, G; Inaba, H; O'Hear, C; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shi, L; Taub, JW | 1 |
| Cui, L; Gao, C; Jiang, J; Li, WJ; Li, ZG; Ma, XL; Mei, YY; Shi, HW; Wang, B; Wang, KL; Wu, MY; Xie, J; Zhang, RD; Zhang, YH; Zhao, W; Zhao, XX; Zhou, X | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Chen, J; Chen, L; Gao, L; Gong, S; Hu, X; Liu, M; Lu, S; Ni, X; Qiu, H; Song, X; Wang, J; Wang, L; Xu, S; Xu, X; Yang, J; Zhang, W | 1 |
| Castaigne, S; Cayuela, JM; Chevret, S; Dombret, H; Hayette, S; Lambert, J; Nibourel, O; Pautas, C; Preudhomme, C; Renneville, A; Rousselot, P; Terré, C | 1 |
| Arnoux, I; Asnafi, V; Baruchel, A; Béné, MC; Brouzes, C; Dombret, H; Fossat, C; Garand, R; Garnache-Ottou, F; Ifrah, N; Jacob, MC; Kuhlein, E; Macintyre-Davi, E; Plesa, A; Robillard, N; Roussel, M; Tkaczuk, J | 1 |
| Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A | 1 |
| Chen, YB; Jiang, J; Li, SD; Li, ZG; Ma, XL; Qin, MQ; Wang, B; Wu, MY; Wu, RH; Wu, Y; Xie, J; Zhang, R; Zhang, RD; Zheng, HY; Zhou, X | 1 |
| Ahn, JS; Chi, HS; Cho, YU; Chung, JS; Eom, HS; Hyun, MS; Jang, S; Joo, YD; Jung, CW; Kim, DH; Kim, DY; Kim, H; Kim, I; Kim, K; Kim, KH; Kim, SD; Kim, YS; Lee, GW; Lee, H; Lee, HS; Lee, JH; Lee, JJ; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Mun, YC; Park, CJ; Park, J; Park, JH; Park, S; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yoon, SS | 1 |
| Goulden, N; Hough, R; Mitchell, C; Moorman, A; Rowntree, C; Vora, A; Wade, R | 1 |
| Campana, D; Pui, CH | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Basso, G; Biondi, A; Fabbri, G; Locatelli, F; Paganin, M; Polato, K; Rizzari, C; Zecca, M | 1 |
| Attarbaschi, A; Basso, G; Dworzak, MN; Gadner, H; Gaipa, G; Husak, Z; Mann, G; Pötschger, U; Printz, D; Ratei, R; Schumich, A | 1 |
| Arima, K; Hasegawa, D; Hori, T; Hosoya, R; Imamura, T; Kato, I; Kitagawa, Y; Manabe, A; Ogawa, C; Takahashi, H; Takusagawa, A; Tsurusawa, M | 1 |
| Asano, H; Hangaishi, A; Hosoi, M; Kurokawa, M; Takahashi, T; Yamamoto, G | 1 |
| Attarbaschi, A; Dworzak, MN; Gadner, H; Haas, OA; Harbott, J; Inthal, A; Janousek, D; König, M; Krehan, D; Mann, G; Möricke, A; Nebral, K; Niggli, F; Panzer-Grümayer, R; Pichler, H; Schrappe, M; Strehl, S; Teigler-Schlegel, A | 1 |
| Borthakur, G; Estey, EE | 1 |
| Airewele, G; Bowman, WP; Campana, D; Cao, X; Coustan-Smith, E; Dahl, G; Degar, B; Downing, JR; Inaba, H; Lacayo, NJ; Leung, W; Meshinchi, S; Onciu, M; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Taub, J | 1 |
| Kantarjian, H; O'Brien, S | 1 |
| Cassileth, PA; Kim, HT; Lazarus, HM; Litzow, MR; Rowe, JM; Tallman, MS; Wiernik, PH | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Blach, L; Borowitz, MJ; Bowman, WP; Camitta, BM; Carroll, AJ; Carroll, WL; Devidas, M; Hunger, SP; Larsen, EL; Linda, SB; Pullen, DJ; Shuster, J; Willman, CL; Winick, N | 1 |
| Ariffin, H; Kwok, CS; Quah, TC; Tay, SK; Yeoh, AE | 1 |
| Attarbaschi, A; Beier, R; Lauten, M; Meissner, B; Möricke, A; Niemeyer, C; Niggli, F; Odenwald, E; Riehm, H; Schrappe, M; Stanulla, M; Zimmermann, M | 1 |
| Czyzewski, K; Debski, R; Jaworska-Posadzy, A; Kolodziej, B; Kubicka, M; Kurylo-Rafinska, B; Piatkowska, M; Pogorzala, M; Styczynski, J; Wysocki, M | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Haferlach, T; Hiddemann, W; Kern, W; Schnittger, S; Schoch, C; Voskova, D | 1 |
| He, Y; Jiang, X; Ma, Y; Song, Z; Wang, S; Zhu, J | 1 |
| Camera, A; Cimino, G; Cuneo, A; Foà, R; Izzo, B; Mancini, M; Mandelli, F; Martinelli, G; Mecucci, C; Pane, F; Picardi, M; Quintarelli, C; Rotoli, B; Saglio, G; Salvatore, F; Specchia, G; Vitale, A | 1 |
| Fonatsch, C; Gaiger, A; Jäger, U; Kainz, B; Schwarzinger, I; Sperr, WR | 1 |
| Breit, S; Flohr, T; Happich, M; Kulozik, AE; Ludwig, WD; Muckenthaler, MU; Schrappe, M; Stanulla, M; Tolle, G | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Kurahashi, S; Narimatsu, H; Sugimoto, T; Sugiura, I; Yamamoto, F | 1 |
| Caron, PC; Finn, RD; Jurcic, JG; Larson, SM; Maslak, P; Miller, WH; Scheinberg, DA; Warrell, RP; Yao, TJ | 1 |
| Bradstock, K; Brisco, J; Enno, A; Hughes, E; McCaul, K; Morley, AA; Neoh, SH; Sykes, PJ; Szer, J | 1 |
| Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M | 1 |
| Chomienne, C; Degos, L; Fenaux, P | 1 |
| Dibenedetto, SP; Lo Nigro, L; Mayer, SP; Rovera, G; Schilirò, G | 1 |
| Burke, PJ; Gore, SD; Weng, LJ | 1 |
| Fasching, K; Gadner, H; Panzer, S; Panzer-Grümayer, ER; Schneider, M | 1 |
| Boros, B; Egyed, M; Földi, J; Páldi-Haris, P; Rumi, G | 1 |
| Diaz, MA; Garcia-Sanchez, F; Madero, L; Martinez, P; Ruano, D; Tutor, O | 1 |
| Behm, FG; Boyett, JM; Campana, D; Coustan-Smith, E; Hancock, ML; Pui, CH; Raimondi, SC; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sancho, J; Sandlund, JT | 1 |
| Botsonis, A; Moschovi, M; Papadopoulou, AL; Tsangaris, GT; Tzortzatou-Stathopoulou, F | 1 |
7 review(s) available for daunorubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bone Marrow; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease Management; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Risk Assessment; RUNX1 Translocation Partner 1 Protein; Sequence Analysis, DNA | 2018 |
Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclophosphamide; Daunorubicin; Humans; Induction Chemotherapy; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Vincristine | 2017 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Core Binding Factors; Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 2010 |
Acute promyelocytic leukemia: biology and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Translocation, Genetic; Tretinoin | 1997 |
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Daunorubicin; Disease-Free Survival; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Infant; Leukemia-Lymphoma, Adult T-Cell; Life Tables; Male; Methotrexate; Neoplasm, Residual; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2001 |
22 trial(s) available for daunorubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate | 2021 |
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm, Residual; Treatment Outcome | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD13 Antigens; CD56 Antigen; Child; Daunorubicin; Humans; Immunophenotyping; Neoplasm, Residual; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Vincristine | 2018 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Genetic Markers; Humans; Mercaptopurine; Methotrexate; Neoplasm, Residual; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Vincristine | 2013 |
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Infant; Leukemia, Biphenotypic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Analysis; Vincristine | 2013 |
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Survival Analysis; Treatment Outcome | 2013 |
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; RNA, Messenger; Treatment Outcome; WT1 Proteins | 2014 |
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubicin; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunophenotyping; Leukocytes, Mononuclear; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Sensitivity and Specificity; Treatment Outcome; Vincristine | 2015 |
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis | 2015 |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vincristine | 2015 |
Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; Dexamethasone; Female; Humans; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2016 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prednisone; Prognosis; Prospective Studies; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; Female; Gene Expression Regulation, Leukemic; Humans; Infant; Male; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Rituximab; Up-Regulation; Vincristine | 2008 |
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 9; Daunorubicin; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Infant; Karyotyping; Male; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 2010 |
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Remission Induction; Survival Rate; Young Adult | 2010 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Thioguanine; Treatment Outcome; Vincristine | 2011 |
Mitochondrial D-loop polymorphisms and mitochondrial DNA content in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Case-Control Studies; Child; Child, Preschool; Chromosome Aberrations; Daunorubicin; Dexamethasone; DNA, Mitochondrial; Female; Fetal Blood; Humans; Male; Mitochondria; Neoplasm, Residual; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Vincristine | 2011 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infant; Lymphocyte Count; Male; Mercaptopurine; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine | 2012 |
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vincristine | 2005 |
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; Dimerization; Female; Humans; Leukocyte Count; Male; Mutation; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Receptor, Notch1; Time Factors; Treatment Outcome; Vincristine | 2006 |
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
41 other study(ies) available for daunorubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia.
Topics: Animals; Apoptosis; Autophagy; Bone Marrow Cells; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; MicroRNAs; Neoplasm, Residual; Stromal Cells; Toll-Like Receptor 2; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Rate; Vincristine | 2020 |
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Infant, Newborn; Lymphoma, B-Cell; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Prednisone; Retrospective Studies; Vincristine | 2020 |
Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Child, Preschool; Cyclophosphamide; Daunorubicin; Dexamethasone; Drug Administration Schedule; Female; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Translocation, Genetic; Transplantation, Haploidentical; Vincristine | 2020 |
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; SARS-CoV-2 | 2020 |
Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Asparaginase; Child; Child, Preschool; Clinical Protocols; Daunorubicin; Female; Fusion Proteins, bcr-abl; Humans; Incidence; Male; Neoplasm, Residual; Poland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Vincristine | 2020 |
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2021 |
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Topics: Adult; Aged; Biomarkers, Tumor; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Young Adult | 2021 |
Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression Profiling; Greece; Humans; Infant; Male; MicroRNAs; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Remission Induction; Risk Assessment; RNA, Neoplasm; Treatment Outcome; Vincristine | 2018 |
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
Topics: Adult; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Drug Substitution; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction | 2019 |
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.
Topics: Antibiotics, Antineoplastic; Child; Cohort Studies; Daunorubicin; Female; Follow-Up Studies; Glucosephosphate Dehydrogenase; Humans; Induction Chemotherapy; Male; Neoadjuvant Therapy; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Risk Factors; Safety | 2019 |
Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Risk; Time Factors; Treatment Outcome; Vincristine | 2019 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Europe; Hematopoietic Stem Cell Transplantation; Humans; Mercaptopurine; Methotrexate; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Retreatment; Survival Rate; Vincristine | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
[Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; Dexamethasone; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Infant; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Treatment Outcome | 2013 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Chromosome Aberrations; Consolidation Chemotherapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prognosis; RUNX1 Translocation Partner 1 Protein; Young Adult | 2014 |
Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia: a single-center experience with 256 cases in China.
Topics: Antineoplastic Agents; Child; Child, Preschool; China; Daunorubicin; Dexamethasone; Female; Humans; Infant; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Vincristine | 2015 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality Therapy; Daunorubicin; Humans; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Orchiectomy; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Testicular Neoplasms; Testis; Vincristine | 2009 |
Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Monocytic, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2010 |
Questions regarding frontline therapy of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Retreatment | 2010 |
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Retreatment | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Male; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Vincristine | 2012 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Prognosis; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thioguanine | 2004 |
[Biological characteristics of residual leukemic cells and their drug-resistant regrowth].
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Leukemia; Male; Mice; Neoplasm, Residual | 1997 |
Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Tretinoin | 2005 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lenograstim; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Tissue and Organ Harvesting | 2008 |
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Neutropenia; Nuclear Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transcription Factors; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 1995 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prednisolone; Recombinant Fusion Proteins; RNA, Messenger; Translocation, Genetic | 1997 |
Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blotting, Southern; Bone Marrow; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; DNA, Neoplasm; Evaluation Studies as Topic; Female; Fluorometry; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Immunophenotyping; Infant; Italy; Leucovorin; Leukemia-Lymphoma, Adult T-Cell; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Stem Cells; Nucleic Acid Hybridization; Polymerase Chain Reaction; Prednisone; Prognosis; Prospective Studies; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Vincristine | 1997 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Middle Aged; Neoplasm, Residual; Remission Induction; Tumor Stem Cell Assay | 1998 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Gene Rearrangement; Humans; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Risk; Time Factors; Treatment Outcome; Vincristine | 2000 |
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Interferons; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Remission Induction; Tretinoin | 2000 |
Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Topics: Adolescent; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Bone Marrow; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; Infant; Leukocyte Count; Male; Neoplasm Proteins; Neoplasm, Residual; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Treatment Outcome; Vincristine | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Etoposide; Female; Flow Cytometry; Humans; Hydrocortisone; Immunophenotyping; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Cells, Circulating; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Vincristine | 2000 |